365 related articles for article (PubMed ID: 30756282)
1. CT characteristics predict the response to everolimus or sirolimus of renal angiomyolipomas in patients with tuberous sclerosis complex.
Wang W; Guo H; Shi B; Sun H; Li H; Zhang Y; Cai Y
Int Urol Nephrol; 2019 Apr; 51(4):671-676. PubMed ID: 30756282
[TBL] [Abstract][Full Text] [Related]
2. Effect of everolimus treatment for renal angiomyolipoma associated with tuberous sclerosis complex: an evaluation based on tumor density.
Hatano T; Atsuta M; Inaba H; Endo K; Egawa S
Int J Clin Oncol; 2018 Jun; 23(3):547-552. PubMed ID: 29256023
[TBL] [Abstract][Full Text] [Related]
3. Effects of everolimus on tuberous sclerosis complex-associated renal angiomyolipoma: A preliminary report.
Tsai JD; Wei CC; Yang SH; Fan HC; Hsu CC; Tung MC; Tsai ML; Sheu JN
Nephrology (Carlton); 2017 Dec; 22(12):1017-1022. PubMed ID: 27565896
[TBL] [Abstract][Full Text] [Related]
4. Everolimus versus sirolimus for angiomyolipoma associated with tuberous sclerosis complex: a multi-institutional retrospective study in China.
Luo C; Zhang YS; Zhang MX; Chen MF; Li Y; Qi L; Li HZ; Zu XB; Cai Y
Orphanet J Rare Dis; 2021 Jul; 16(1):299. PubMed ID: 34217357
[TBL] [Abstract][Full Text] [Related]
5. The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, Phase 3 trial EXIST-1.
Kingswood JC; Jozwiak S; Belousova ED; Frost MD; Kuperman RA; Bebin EM; Korf BR; Flamini JR; Kohrman MH; Sparagana SP; Wu JY; Brechenmacher T; Stein K; Berkowitz N; Bissler JJ; Franz DN
Nephrol Dial Transplant; 2014 Jun; 29(6):1203-10. PubMed ID: 24729041
[TBL] [Abstract][Full Text] [Related]
6. Effect of everolimus treatment for regrown renal angiomyolipoma associated with tuberous sclerosis complex after transcatheter arterial embolization.
Hatano T; Matsu-Ura T; Mori KI; Inaba H; Endo K; Tamari M; Egawa S
Int J Clin Oncol; 2018 Dec; 23(6):1134-1139. PubMed ID: 30069798
[TBL] [Abstract][Full Text] [Related]
7. Assessing the outcomes of everolimus on renal angiomyolipoma associated with tuberous sclerosis complex in China: a two years trial.
Cai Y; Guo H; Wang W; Li H; Sun H; Shi B; Zhang Y
Orphanet J Rare Dis; 2018 Mar; 13(1):43. PubMed ID: 29587809
[TBL] [Abstract][Full Text] [Related]
8. Treatment effect of mTOR-inhibition on tissue composition of renal angiomyolipomas in tuberous sclerosis complex (TSC).
Brakemeier S; Vogt L; Adams L; Zukunft B; Diederichs G; Hamm B; Budde K; Makowski MR
PLoS One; 2017; 12(12):e0189132. PubMed ID: 29232371
[TBL] [Abstract][Full Text] [Related]
9. Continuous low-dose everolimus shrinkage tuberous sclerosis complex-associated renal angiomyolipoma: a 48-month follow-up study.
Wei CC; Tsai JD; Sheu JN; Chen SL; Tsao TF; Yang SH; Tsai JD
J Investig Med; 2019 Mar; 67(3):686-690. PubMed ID: 30455224
[TBL] [Abstract][Full Text] [Related]
10. The association between computed tomography attenuation value of renal angiomyolipoma associated with tuberous sclerosis complex and response to everolimus.
Liao Z; Li J; Zhao Y; Wang Z; Wang X; Qiu D; Zhang Y
World J Urol; 2024 Jan; 42(1):10. PubMed ID: 38183428
[TBL] [Abstract][Full Text] [Related]
11. Regression of renal angiomyolipomas with oral rapamycin therapy in a patient with tuberous sclerosis complex disease.
Torun D; Micozkadioglu H; Gedikoglu M; Ozelsancak R; Tekkarismaz N
Saudi J Kidney Dis Transpl; 2019; 30(2):545-548. PubMed ID: 31031395
[TBL] [Abstract][Full Text] [Related]
12. Rapamycin and rapalogs for tuberous sclerosis complex.
Sasongko TH; Ismail NF; Zabidi-Hussin Z
Cochrane Database Syst Rev; 2016 Jul; 7(7):CD011272. PubMed ID: 27409709
[TBL] [Abstract][Full Text] [Related]
13. Sirolimus and tuberous sclerosis-associated renal angiomyolipomas.
Krischock L; Beach R; Taylor J
Arch Dis Child; 2010 May; 95(5):391-2. PubMed ID: 20457704
[TBL] [Abstract][Full Text] [Related]
14. Mutational analysis of renal angiomyolipoma associated with tuberous sclerosis complex and the outcome of short-term everolimus therapy.
Ni J; Yan F; Qin W; Yu L; Zhang G; Liu F; Yang X; Yang B; Hao C; Wang T; Liu P; Yuan J; Wu G
Sci Rep; 2019 Oct; 9(1):14337. PubMed ID: 31586081
[TBL] [Abstract][Full Text] [Related]
15. Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial.
Bissler JJ; Kingswood JC; Radzikowska E; Zonnenberg BA; Frost M; Belousova E; Sauter M; Nonomura N; Brakemeier S; de Vries PJ; Berkowitz N; Miao S; Segal S; Peyrard S; Budde K
Nephrol Dial Transplant; 2016 Jan; 31(1):111-9. PubMed ID: 26156073
[TBL] [Abstract][Full Text] [Related]
16. Lymphangioleiomyomatosis.
Johnson SR; Taveira-DaSilva AM; Moss J
Clin Chest Med; 2016 Sep; 37(3):389-403. PubMed ID: 27514586
[TBL] [Abstract][Full Text] [Related]
17. The effect of everolimus on renal angiomyolipoma in pediatric patients with tuberous sclerosis being treated for subependymal giant cell astrocytoma.
Bissler JJ; Franz DN; Frost MD; Belousova E; Bebin EM; Sparagana S; Berkowitz N; Ridolfi A; Kingswood JC
Pediatr Nephrol; 2018 Jan; 33(1):101-109. PubMed ID: 28993887
[TBL] [Abstract][Full Text] [Related]
18. Angiomyolipoma rebound tumor growth after discontinuation of everolimus in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis.
Bissler JJ; Nonomura N; Budde K; Zonnenberg BA; Fischereder M; Voi M; Louveau AL; Herbst F; Bebin EM; Curatolo P; Zonta A; Belousova E
PLoS One; 2018; 13(9):e0201005. PubMed ID: 30192751
[TBL] [Abstract][Full Text] [Related]
19. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
MacKeigan JP; Krueger DA
Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
[TBL] [Abstract][Full Text] [Related]
20. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial.
Bissler JJ; Kingswood JC; Radzikowska E; Zonnenberg BA; Frost M; Belousova E; Sauter M; Nonomura N; Brakemeier S; de Vries PJ; Whittemore VH; Chen D; Sahmoud T; Shah G; Lincy J; Lebwohl D; Budde K
Lancet; 2013 Mar; 381(9869):817-24. PubMed ID: 23312829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]